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ABSTRACT 
 
 
 
Introduction. Venous thromboembolism (VTE), including deep vein thrombosis (DVT) 
and pulmonary embolism (PE), is a common condition with significant rates of morbidity 
and mortality. VTE can lead to such complications as post-thrombotic syndrome (PTS) 
and chronic thromboembolic pulmonary hypertension (CTEPH). Accurate and prompt 
diagnosis of PE is the prerequisite for therapies to reduct the morbidity and mortality in 
PE. In recent years, guidelines have given diagnostic strategies based on clinical 
probabilities, D-dimer levels, ultrasonography of the legs, and computed tomography. The 
diagnostic tools have become more precise, and increasingly rapid diagnostic methods are 
being sought. However, late effects and consequences of VTE have rarely been the focus 
of interest in publications. 
 
Aims of the study. We aimed to develop a sensitive, fully quantitative, and automated 
POC (point-of-care) testing assay for D-dimer in whole blood with the shortest possible 
assay time. A second aim was to determine the value of CT and NT-proBNP in detection 
of right ventricular dysfunction (RVD) in the acute phase and during follow-up of non-
high-risk acute pulmonary embolism in clinical practice. Third, the membrane and 
pulmonary capillary blood volume components of diffusing capacity at the acute stage of 
PE was studied to identify which parameters are associated with right ventricular 
overload. Concerning the long-term effects of DVT, a fourth aim was to determine the 
prevalence of reflux patterns in patients with iliofemoral venous thrombosis 2-3 years after 
systemic or catheter-directed thrombolysis. 
 
Patients and methods. The study consists of four projects. 
1. The blood samples of patients (n=525) and healthy volunteers (n=101) were involved. 
The plasma samples were analyzed either fresh or stored at -20°C or -70°C until used. The 
simple, automated assay procedure comprised a 1:50 sample dilution, one-step incubation, 
washing, and time-resolved fluorometric measurement directly from the wet assay wells. 
The Roche Diagnostic TinaQuant® D-dimer (Knecht MF et al. 1997) and the Biopool 
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Auto Dimer ® (Bozic M et al. 2003) assays were used as comparison methods in the 
study. 
2. Sixty-three non-high-risk APE patients were studied. RVD was assessed at admission to 
the emergency department by computed tomography (CT), transthoracic 
echocardiography (TTE), cardiac biomarkers (NT-proBNP and cardiac troponin T), blood 
gases, electrocardiogram (ECG), and clinical evaluation. TTE, cardiac biomarkers, and 
clinical evaluation were repeated 7 months later. 
3. Forty-seven patients with acute non-high-risk PE confirmed by CT were included. The 
extent of PE was assessed by scoring mass of embolism. Measurements of diffusing 
capacity for carbon monoxide (DL,CO), diffusing capacity of alveolocapillary membrane 
(DM), pulmonary capillary blood volume (Vc), and alveolar volume (VA) were measured 
at the acute event and 7 months later. RVD was evaluated with TTE and ECG. Fifteen 
healthy subjects were included as controls. 
4. Thirty-seven patients with ileofemoral deep venous thrombosis treated with either 
systemic or catheter-directed thrombolysis were evaluated 2-3 years after the thrombotic 
event. The evaluation was performed with CEAP (clinical, etiological, anatomical, 
pathophysiological) classification and color duplex ultrasound. Patients were also asked to 
fill in the questionnaire concerning risk factors, duration of anticoagulation therapy, and 
use of compression stockings. 
 
Results. 
1. Achieving the steady-state in the one-step assay took 60 min. Of the steady-state values 
approximately 45% were reached in 10 minutes incubation time. The analytical detection 
limit of the assay was 0.046 mg/l (calculated as the mean background signal +3 SD). The 
within- and between-assay imprecision was similar for whole-blood and plasma samples, 
ranging from 8.3% to 13% below and from 3.8% to 7.7% above the cut-off level of 0.6 
mg/l. The within- and between-assay imprecision was also calculated for commercial D-
dimer controls from Bio-Rad and Biopool and showed a corresponding imprecision. When 
using the cut-off values of 0.6 and 1.0 mg/l, clinical sensitivities and specificities were 
98.7% and 64.4%, and 62.2 % and 81.0%, respectively. 
2. Right ventricular overload was detected with CT in 37 (59%) of 63 patients. Twenty-
eight patients (76%) in the RVD-positive group also had signs of RVD in TTE. Nine of 
the RVD-positive patients (24%) showed no echocardiographic alterations in RV 
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morphology or function. Altogether findings of RVD in CT were congruent with those in 
echocardiography (p<0.0001). Patients who had RVD in CT had elevated NT-proBNP 
relative to patients with no RVD (87% vs. 27%, p<0.0001). In the RVD-positive group, 32 
(86.5%) of 37 patients had signs of RVD in ECG, whereas 8 patients (13%) had such 
findings in the RVD-negative group (p<0.0001). In the 7-month follow-up, RVD was 
detected in 6 (10%) of 63 patients. These patients had also elevated NT-proBNP levels 
(p<0.0001). All patients who were found to have persistent RVD had RVD in both CT and 
TTE on admission. 
3. DL,CO, DL, DM, vital capacity (VC) and VA were lower in patients with acute PE than 
in healthy controls (p<0.001). DM correlated inversely with central mass of embolism 
(r=-0.312; p=0.047), whereas Vc did not. DM, DL,CO, VC, and VA improved 
significantly within 7 months. In all patients (p=0.001, p=0.001) and persistent RVD 
patients (p=0.020, p=0.012), DM, DL,CO remained significantly lower than in healthy 
controls at follow-up. DM was inversely related to central mass of embolism. 
4. In both catheter-directed thrombolysis and systemic lysis-treated patient groups, 38% of 
the patients were using warfarin permanently at the follow-up visit. In the rest of the 
patients in both groups, the mean duration of warfarin treatment was 8 months. Risk 
factors, including genetic defects, were found in 50% of catheter-directed and 75% of 
systemic-treated patients (p=0.25). Fifty percent of catheter-directed lysis and 38% of 
systemic lysis-treated patients had used or were still using compression stockings 
(p=0.41). Valvular competence was preserved in 44% of patients treated with catheter-
directed thrombolysis compared with 13% of those treated systemically (p=0.01). Any 
deep reflux was present in 44% of catheter-directed lysis-treated patients compared with 
81% of systemic-treated patients (p=0.03). Any superficial reflux was observed in 25% 
and 63% of the patients, respectively (p=0.03). Patients treated with catheter-directed 
thrombolysis tended to have a better clinical status based on evaluation by CEAP 
classification at follow-up. 
 
Conclusions 
1. The rapid and sensitive 10-min D-dimer assay seems to be suitable for excluding VTE 
in POC settings. Based on the high preliminary sensitivity and negative predictive value 
obtained here, the assay could potentially be used as a stand-alone test given that a 
sufficiently low cut-off level was selected. Alternatively, combined with clinical 
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probability assessment, a higher cut-off level could be used to increase the specificity of 
the assay. 
2. The study of 63 patients with APE shows that CT is a practical and valuable imaging 
method for detection of RVD in non-high-risk APE patients. All patients found to have 
RVD at the 7-month follow-up had RVD also in the acute phase CT and TTE. According 
to these results, a follow-up protocol is suggested. Patients with RVD on admission CT 
should be rescreened with natriuretic peptide assessment at follow-up and if elevated an 
echocardiography should be performed. Timing for screening is reasonable at the visit 
where warfarin is to be discontinued. Alternatively, if anticoagulation therapy is deemed 
continuous at discharge, then biomarker screening might be done during a routine follow-
up visit 6-12 months after APE. The suggested protocol needs to be validated in a larger 
patient population. 
3. The extent of PE and subsequent signs of RVD were associated with a decrease in 
diffusion capacity of membrane in both the acute phase and in the resolution phase of PE 
independent of lung volume changes. In patients with permanent RVD, also the total 
diffusing capacity remained decreased in the follow-up. The diffusing capacity recovered 
during the 7-month follow-up, but did not reach the level of healthy controls or the normal 
reference range. Study data provide new knowledge of consequences of PE on lung 
function, indicating that sustained reduction in diffusing capacity may remain despite 
treatment of PE according to current guidelines. 
4. Catheter-directed thrombolysis for DVT at the acute event reduced both deep and 
superficial reflux at the 2- to 3-year follow-up.  
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1. INTRODUCTION 
 
 
 
Venous thromboembolism (VTE) is a multifactorial disease with both environment- and 
genetic-related risk factors. VTE presents clinically as deep venous thrombosis (DVT) and 
pulmonary embolism (PE), with serious outcome in both men and women. PE is the third 
most common cause of death from cardiovascular disease after heart attack and stroke 
(Naess IA et al. 2007).  
Over the past two decades, new diagnostic and prognostic tools (e.g. D-dimer, 
computer tomography, cardiac biomarkers) have been developed, improving the care of 
patients with suspected or diagnosed VTE. Clinical probability assessment nowadays 
helps to identify patients with a high or intermediate risk and those in need of 
anticoagulation treatment while awaiting the results of the tests. Low-risk patients can be 
identified as well. The probability can be assessed with prediction rules or scores during 
the acute phase. 
VTE can be diagnosed by various cost-effective diagnostic algorithms in combination 
with non-invasive imaging techniques. Pharmacological and non-pharmacological 
interventions can be used to prevent and manage these conditions. The combination of 
both interventions may ease the process of prevention and treatment of VTE (Moheimani 
F et al. 2011). 
There are several earlier studies examining short-term effects of PE. A paucity of 
literature also exists concerning long-term course of PE (Carson JL et al. 1992, Ribeiro A 
et al. 1999, Sharma GV et al. 2000, Poulsen SH et al. 2001, Pengo V et al. 2004, Becattini 
G et al. 2005), and most of these studies have investigated mortality as the study endpoint. 
In spite of the uncomplicated clinical course of most VTE patients, VTE also can cause 
significant complications, including recurrent thrombotic events, PTS, and CTEPH. PTS 
can be seen in about one-third of DVT patients (Prandoni P et al. 1996). Pulmonary 
hypertension, in turn, is detected in 4-5% of PE sufferers (Pengo V et al. 2004). Early 
identification of patients at risk for CTEPH is important so that these patients can be 
referred for further evaluation of relevant diagnostic and therapeutic strategies. 
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2. REVIEW OF THE LITERATURE 
 
 
 
2.1 Pathophysiology 
 
PE and DVT are parts of the same process, venous thromboembolism. DVT can be found 
in about 70% of patients with PE. Rarely, the source of emboli can be upper extremity 
veins, iliac veins, renal veins, or right heart (Riedel 2001). The mortality of untreated PE 
is estimated to be approximately 30%; adequate treatment reduces this figure to 2-8% 
(Goldhaber et al. 1999). 
The annual incidence of VTE is 100 persons per 100 000 in the United States, rising 
exponentially with age. Despite anticoagulation therapy, the 6-month recurrence rate of 
VTE was approximately 6% in the California Patient Discharge data set (Murin S et al. 
2002). Death occurs in 6% of DVT patients and 12% of PE patients within one month of 
diagnosis, and early mortality after VTE diagnosis is strongly associated with presentation 
as PE, advanced age, cancer, and underlying cardiovascular disease (White RH 2003). The 
risk of fatal PE is 2-to 3-fold higher after an episode of PE than DVT (Douketis JD et 
al.1998, Heit JA et al. 1999, Murin S et al. 2002). 
Hemodynamic consequences of PE appear when over 30-50% of the pulmonary 
arterial bed is occluded by thromboemboli (McIntyre KM et al. 1971). The effects of an 
embolus depend on the extent to which it obstructs the pulmonary circulation, the 
localization over which the obstruction accumulates, and the pre-existing condition of the 
patient. As a result, pulmonary hypertension may develop disproportionate to the amount 
of vasculature that is mechanically occluded. Most emboli are multiple. As both the extent 
and chronicity of obstruction vary widely, PE can produce markedly differing clinical 
pictures (Riedel M 2001). 
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2.2 Risk factors of venous thromboembolism (VTE) 
 
The proportion of patients with idiopathic or unprovoked PE was about 20% in the 
International Cooperative Pulmonary Embolism Registry (ICOPER) (Goldhaber SZ et al 
1999). A prior episode of lower extremity DVT is the greatest risk factor for a subsequent 
episode of DVT (Kakkar VV et al. 1970). VTE can be seen as a result of a interaction 
between patient-related and setting-related risk factors (Heit JA et al. 2002, Alikhan R et 
al. 2004). Setting-related predisposing factors are quite often temporary, whereas patient-
related factors are usually permanent.  
Predisposing factors for VTE are listed in Table 1. It is important to recognize that the 
predictive values of predisposing factors are not equal. In assessing the need for 
prophylaxis, both the strength of individual risk factors and the cumulative weight of all 
risk factors should be considered. 
 
Table 1. Risk Factors for VTE (adapted from Anderson et al. 2003). 
Strong risk factors (odds ratio >10)
Fracture (hip or leg)
Hip or knee replacement
Major general surgery
Major trauma
Spinal cord injury
Moderate risk factors (odds ratio 2–9)
Arthroscopic knee surgery
Central venous lines
Chemotherapy
Congestive heart or respiratory failure
Hormone replacement therapy
Malignancy
Oral contraceptive therapy
Paralytic stroke
Pregnancy, postpartum
Previous venous thromboembolism
Thrombophilia
Weak risk factors (odds ratio <2)
Bed rest >3 days
Immobility due to sitting (e.g. prolonged car or air travel)
Increasing age
Laparoscopic surgery (e.g. cholecystectomy)
Obesity
Pregnancy, antepartum
Varicose veins  
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A spectrum of inherited risk factors, thrombophilia, contributes to VTE (De Stefano et al. 
1996, Anderson FA 2003, Rosendaal FR et al. 2009). They are also broken down into 
strong, medium, and weak genetic risk factors (Roosendaal FR et al. 2009). Deficiencies 
of some natural coagulation inhibitors, including antithrombin, protein C, and its cofactor 
protein S, insufficiency in such anticoagulants as tissue factor pathway inhibitor, 
thrombomodulin, and endothelial protein C receptor, and an elevated level of factor VIII 
are examples of strong genetic risk factors. Moderate genetic risk factors consist of a 
mutation in factor V Leiden, causing resistance to activated protein C (APC resistance), 
and a mutation in part of the prothrombin gene (prothrombin 20210A) (Moheimani F et al. 
2011). 
Most hospitalized patients should receive pharmacological prophylaxis to minimize 
the risk of VTE (Cohen AT et al. 2008, Dentali F et al. 2007, Guyatt GH et al. 2012, 
Tapson VF et al. 2007). Although a large number of medical and surgical patients have 
risk factors for DVT, prophylaxis often remains underused. In the multicenter cross-
sectional ENDORSE study, 52% of the enrolled patients were at moderate risk for 
developing VTE. Surgical patients received more often prophylaxis than medical patients, 
58% vs. 40% (Cohen et al 2008). It also has been proposed that additional lifestyle risk 
factors, such as cigarette smoking, overweight, metabolic syndrome, hypertension, high 
red meat consumption, and hyperlipidemia, should be considered in preventing both 
myocardial infarction and VTE (Goldhaber SZ 2010). An association has been shown 
between atherosclerotic disease and spontaneous venous thrombosis (Prandoni P et al. 
2003). Shared risk factors and pathophysiology help to understand the increased risk of 
VTE in patients with atherothrombosis and the greater frequency of atherothrombotic 
events in patients with VTE (Piazza G et al. 2010). 
 
2.3 Clinical findings and diagnosis of VTE 
 
2.3.1 Clinical presentation and assessment of clinical probability 
 
Notably, three-quarters of patients who present with suspected DVT have non-thrombotic 
causes of leg pain (O`Donnell T et al. 1980). DVT most often initiates in the calf veins. 
The majority of distal DVT likely resolves spontaneously with no symptoms; patients 
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more often become symptomatic when distal DVT extends to the popliteal and femoral 
veins and other proximal veins (Kearon C et al. 2003). 
Commonly reported symptoms in patients with suspected DVT include leg pain, 
swelling, and other signs such as pitting edema, warmth, dilated superficial veins, and 
erythema (Haeger K et al. 1969, O Donnell T et al. 1980, Hull RD et al.1984). 
The clinical symptoms and signs of DVT and PE are often non-specific. A clinical 
model for predicting probabilities for DVT has been suggested, where different clinical 
features can be scored (Wells PS et al.1997, Le Gal G et al. 2006). By using these rules, 
the proportion of PE is 10% in the lower and 30-65% in the higher clinical probability 
category (Torbicki A et al. 2008). About two-thirds of patients presenting with suspected 
DVT or PE do not have these conditions. Sometimes PE presents in such dramatic way 
that the diagnosis is obvious and treatment is started immediately (Riedel M 2001). 
Typical symptoms of PE are dyspnea, chest pain, cough, hemoptysis, and syncope. 
Clinical signs and symptoms are not, however, very useful since they are not sensitive or 
specific for PE (Torbicki A et al. 2008). 
Clinical probability assessment aims to identify patients with a high or intermediate 
clinical probability of needing immediate treatment. In patients with a low clinical 
probability, VTE can be ruled out solely with a normal D-dimer test (Figure 1). 
 
 
 
 
Figure 1. A diagnostic algorithm for clinically suspected DVT or PE. 
Use of compression ultrasonography (CUS) with suspected DVT (adapted from Goldhaber et al. 
2012). 
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Clinical probability includes clinical history as well as symptoms, signs, and abnormalities 
of oxygen saturation, chest radiography, and ECG. There are two widely used scores: the 
Wells prediction score (Wells PS et al. 2000) and the revised Geneva scores (Le Gal G et 
al. 2006). Scoring systems can help to assess the probability of suspected DVT or PE 
(Table 2). 
 
Table 2. Clinical probability assessment 
 
 
Scoring systems used to assess probability of suspected DVT or PE on the basis of items and 
assigned points. DVT=deep vein thrombosis. PE=pulmonary embolism. 
* Patients with a score of 0 are low risk, 1–2 are intermediate risk, and ≥3 are high risk. 
† For the initial rule, patients with a score of 0–1 are low risk, 2–6 are intermediate risk, and ≥7 
are high risk; for the dichotomized rule, patients are unlikely or likely to have PE if they have 
scores ≥4 and ≤4, respectively. 
‡ Patients with a score <2 are low risk, 2–6 are intermediate risk, and ≥6 are high risk 
(with permission of Elsevier, Goldhaber SZ et al. 2012).  
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The evidence strongly supports the use of clinical prediction rules for establishing the 
pretest probability of DVT or PE in a patient before more definitive testing. The pretest 
probability can then be used in interpreting subsequent test results. The use of D-dimer 
assay with a clinical prediction rule may even have a negative predictive value high 
enough to obviate the need for imaging studies in many low-risk patients (Segal JB et al. 
2007). 
 
2.3.2 D-dimer assay 
 
D-dimer is a degradation product of cross-linked fibrin. It is elevated in conditions where 
fibrin is formed and degraded (VTE, surgery, trauma, hemorrhage, ischemic heart disease, 
cerebrovascular event, infections, malignancy, peripheral arterial disease and aneurysms, 
pregnancy, advanced age of patients, extensive burns) (Palareti G 2006, Adam SS 2009). 
There are a numerous D-dimer assays available nowadays (Stein PD 2004, Di Nisio M 
2007). 
ELISA and ELISA-derived assays have a sensitivity of over 95% and specificity of 
approximately 40%. A negative ELISA can rule out PE in up to 30% of patients (Perrier A 
et al. 1999, Wells PS et al. 2001, Perrier A et al. 2004). 
D-dimer assays have restricted specificity and are less useful than other measures in 
some patient groups, including patients with high clinical probability, patients admitted to 
hospital for some other reason but in whom the suspicion of PE is raised during hospital 
stay, patients older than 65 years, and pregnant women (Righini M et al. 2005, Righini M 
et al. 2008). A normal D-dimer assay can be used in low-to high-risk patients as a reliable 
tool for the exclusion of VTE (Stein PD et al. 2004, Adam SS et al. 2009).  
In clinical diagnostics, there are two ways to organize laboratory services: automation 
and centralization in central laboratories (Hoffmann GE et al. 1998, Wheeler MJ 2001) or 
testing in local laboratories near the patients (St-Louis P. 2000, Price CP et al. 2004). The 
total process of clinical testing using a central laboratory often contains many additional 
steps. In answer to the growing need for rapid diagnostics, point-of-care testing (POCT) 
has been developed in recent years. POCT is defined any testing near the patient (St-Louis 
P 2000, Price CP et al. 2004). It is performed by personnel with minimal practice and 
experience in laboratory procedures. The tests are mainly available within 2-20 minutes. 
The settings for the POCT include primary care settings, ambulances and other transport 
REVIEW OF THE LITERATURE 
19 
 
settings, emergency units, and other hospital units (Hicks JM et al. 2001, Hardy RW et al. 
2004, Kirkbride RE 2004). In a study of diagnostic accuracy of POCT for thromboembolic 
events in primary care, the D-dimer assay showed value in excluding VTE (Tomonaga Y 
et al. 2011). POCT can be more expensive than testing performed in a central laboratory. 
Nevertheless, POCT technologies can improve emergency department measures such as 
length of stay (Lee-Lewandrowski E et al. 2009). 
 
2.3.3 Compression ultrasonography 
 
Compression ultrasonography (CUS) as a simple, non-invasive procedure is the method of 
choice in evaluating lower limb veins for DVT (Fraser JD et al.1999, Palareti G et al. 
2006, Tan M et al. 2009). CUS has a sensitivity of over 90% for proximal DVT and a 
specificity of about 95% (Perrier A et al.1998, Kearon C et al. 1998). Use of ultrasound in 
diagnosing symptomatic thrombosis in the proximal veins of the lower limb is 
recommended for patients whose pretest probability of disease falls in the category of high 
risk of DVT under the Wells prediction rule. Ultrasound is less sensitive in patients who 
have DVT limited to the calf veins; the sensitivity of venous ultrasound is only 73% 
(Kearon C et al. 1998). Therefore, a negative ultrasound does not rule out DVT in these 
patients. A repeated ultrasound may be required for patients who have suspected calf vein 
DVT and a negative ultrasound and for patients who have suspected proximal DVT and an 
ultrasound that is technically inadequate or equivocal (Qaseem A et al. 2007). 
 
2.3.4 Arterial blood gas analysis 
 
Arterial blood gas analysis is one of the clinical examinations in patients with suspected 
PE. It can help in evaluation of gas exchange and acid-base status of a suspected PE 
patient. Hypoxemia or hypocapnia in arterial blood gas analysis can be detected, but 
results may also be normal, especially in younger patients without previous 
cardiopulmonary disease (Stein PD 1991). PE is usually associated with hypoxemia, but 
20% of patients with PE have a normal arterial oxygen pressure (Stein PD et al. 1996). In 
the setting of a normal or near-normal chest radiograph and significant unexplained 
hypoxemia, PE should be considered (Tapson VF et al. 2012). In conclusion, blood gases 
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may heighten the suspicion of PE and contribute to the clinical assessment, but they are of 
insufficient discriminative value to confirm or exclude the diagnosis of PE. 
 
2.3.5 Electrocardiogram 
 
The electrocardiogram (ECG) can show in patients with APE inverted T-waves in leads 
V1-V4, QR-pattern in lead V1, S1Q3T3 pattern, and incomplete or complete right bundle-
branch block. Especially if the findings are new at onset of APE, ECG can be helpful 
(Rodger M et al. 2000, Geibel A et al. 2005). However, ECG findings in APE are non-
specific (Rodger M et al. 2000). The S1Q3T3 pattern may be present on the ECG, but it is 
non-specific. With extensive emboli, a right ventricular strain pattern may be present, 
which also can be considered with regard to determining the level of aggressiveness of 
therapy in proven PE (Tapson VF 2012). 
 
2.3.6 Computed tomography 
 
Computed tomography pulmonary angiography (CTPA) has become the first-line 
examination for the detection of APE (Costello P et al. 2000, Schoepf UJ et al. 2002, 
Schoepf UJ et al. 2003, Schoepf UJ et al. 2004). CTPA is available in most hospitals 
nowadays, and it is fast and easy to perform (British Thoracic Society Standards of Care 
Committee Pulmonary Embolism Guideline Development Group 2003). New-generation 
CT scans are also able to visualize subsegmental arteries (Raptopoulos V et al. 2001, 
Schoepf UJ et al. 2002). While multidetector CT is quite sensitive, small, subsegmental 
emboli are sometimes difficult to visualize. If a study is suboptimal or if findings are 
uncertain, additional ultrasound of the leg or lung imaging should be considered (Tapson 
VF 2012). The quantitative assessment of CTPA correlates well with clinical severity 
(Bankier AA et al. 1997, Mastora I et al. 2003). CTPA is also useful in demonstrating 
alternative diagnoses when PE is excluded. Furthermore, several studies have suggested 
that CTPA is helpful in detecting RVD (Araoz PA et al. 2003, Schoepf UJ et al. 2004, WU 
AS et al. 2004, Quiroz R et al. 2004, Van der Meer RW et al. 2005, Ghaye P et al. 2006, 
Araoz PA et al. 2007). Signs of RVD include a high ratio of the right ventricle to the left 
ventricle on CTPA (Reid JH et al. 1998, Contractor S et al. 2002, Araoz PA et al. 2002), a 
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bowing interventricular septum, and reflux of contrast medium into the inferior vena cava 
(Collomb D et al. 2003, Aviram G et al. 2008). 
 
2.3.7 Echocardiography 
 
RVD has been consistently detected with TTE in approximately 50% of APE patients 
(Kasper W et al. 1997, Ribeiro A et al. 1997, Goldhaber SZ 1999, Kreit JW et al. 2004). 
Echocardiographic criteria used for RVD have varied in different studies. The most 
commonly used qualitative echocardiographic assessment of RVD is wall motion 
(Goldhaber SZ et al. 1993, Wolfe MW et al. 1994, Ribeiro A et al. 1997, Goldhaber SZ et 
al. 1999), which is evaluated as normal or mildly, moderately, or severely hypokinetic. 
The basic quantitative criterion is RV dilatation (Kasper W et al. 1997, Grifoni S et al. 
2000). The presence of pulmonary hypertension has also been applied as a diagnostic 
criterion (Kasper W et al. 1997, Ribeiro A et al. 1997, Grifoni S et al. 2000). Continuous 
wave Doppler is used to estimate the pulmonary artery systolic pressure by measuring the 
peak velocity of the tricuspid valve and pulmonary valve. The gradient across the tricuspid 
valve can be calculated by using the modified Bernoulli formula (Dabestani A et al. 1987). 
Estimated right atrial pressure is added to the gradient to estimate pulmonary artery 
pressure. Hepatic venous flow can also be used to estimate right atrial pressure (Omnen 
SR et al. 2000). A relatively new method is the Doppler-derived index (TEI index) to 
assess overall RV function. The index is defined as the isovolumic contraction time and 
isovolumic relaxation time divided by the ejection time (Tei et al. 1996). An increased RV 
TEI index is associated with either LV diastolic abnormalities or pulmonary hypertension 
(Tei Cetal 1995, Giunta A et al. 2000, Vonk MC 2007). 
Many authors have based the diagnosis of RVD on various combinations of these 
findings. It is unknown which of these criteria is the most sensitive indicator of PE-
induced RVD since data on the issue are limited (McConnell MV 1996, Kurzyna M et al. 
2002, Kreit JW et al. 2004). In any case, peak of tricuspidal gradient is the most 
commonly used method to assess pulmonary artery systolic pressure in clinical practice 
(Chan KL et al. 1987). 
In patients in critical condition with shock or hypotension, bedside TTE can help in 
making management decisions. The absence of signs of RVD excludes PE as a cause of 
hemodymamic instability. In these clinical situations, TTE can be helpful in differential 
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diagnosis of other causes of shock by, for example, detecting cardiac tamponade, acute 
valvular dysfunction, or acute myocardial infarction. On the other hand, if there are signs 
of RVD in a hemodynamically stable patient with suspected PE, echocardiographic 
diagnostic tools can justify aggressive treatment because of the patient’s critical condition. 
The main role of TTE in non-high-risk PE is further prognostic stratification to the 
intermediate- or low-risk category (Torbicki A et al. 2008). 
 
2.3.8 Cardiac biomarkers 
 
Increased myocardial stretch leads to the release of brain natriuretic peptide (BNP) and 
cardiac troponins. High levels of BNP, pro-BNP, and cardiac troponin have been 
associated with an elevated risk of death in patients with APE (Kostrubiec M et al. 2005, 
Becattini C et al. 2007). Elevated natriuretic peptides BNP and NT-proBNP are predictive 
of adverse short-term outcome in patients with APE (Tulevski II et al. 2001, Kucher N et 
al. 2003, Pruszczyk P et al. 2003, Ten Wolde M et al. 2003, Krüger S et al. 2004, Pieralli 
F et al. 2006, Kostrubier M et al. 2007, Alonso-Martinez II et al. 2009). However, 
although elevated BNP and pro-BNP levels are associated with worse outcome, their 
positive predictive value is quite low (12-26%) (Perrier A et al. 1999, Kruip MJ et al. 
2002, Perrier A et al. 2004, Van Belle A et al. 2006). Low levels of BNP or NT-pro-BNP, 
by contrast, can be utilized for identification of patients with a good prognosis concerning 
short-term mortality or clinical outcome (Kucher N et al. 2003, Pruszczyk P et al. 2003, 
Ten Wolde M et al. 2003, Binder L et al. 2005, Kostrubier M et al. 2007). A systematic 
review of evaluating the accuracy of BNP or NT-proBNP for the diagnosis of RVD has 
indicated that BNP and NT-proBNP are associated with the diagnosis of RVD in patients 
with acute PE and are significant predictors of all-cause in-hospital or short-term mortality 
in these patients (Cavallazzi et al. 2008). The results of another meta-analysis concerning 
troponin-based risk stratification showed that the prognostic value of troponin levels in 
normotensive APE patients depends greatly on the cut-off points used (Jimenez D et al. 
2009). 
Some novel biomarkers, such as heart-type fatty acid-binding protein (H-FABP), an 
early marker of myocardial injury, have also been demonstrated to have prognostic value 
(Kaczynska A et al. 2006, Puls M et al. 2007, Dellas C et al. 2010). 
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2.3.9 Lung function parameters 
 
APE has been shown to be associated with decreased pulmonary diffusing capacity, 
reflecting deterioration of gas exchange capacity of the lungs (Sharma GV et al. 1980). 
Lung diffusing capacity refers to the ability of the lungs to transfer gases between the 
alveolar and pulmonary capillary compartments and is most frequently quantified by the 
rate of uptake of carbon monoxide (CO) during breath-holding or rebreathing maneuvers 
(Sackrer M et al. 1975, Meyer M et al. 1990, Hsia CC et al. 2002, Stam H et al. 1983, 
Snyder EM et al. 2005). 
The simplified model described by Roughton and Forster is widely accepted as the 
standard for quantifying lung diffusing capacity. It describes a series of resistances: the 
diffusion of the gas across the alveolocapillary membrane, the transfer into the plasma and 
across the red blood cell membrane, and the chemical reaction of the gas with hemoglobin 
(Roughton FJ et al. 1957). Measurement of diffusing capacity (DL) is informative for 
pathophysiologic diagnoses of lung diseases, and serial measurements are used to follow 
the course of disease (Macintyre N et al. 2005). A few studies have attributed the low DL 
to a loss of diffusing capacity of alveolocapillary membrane (DM) rather than vital 
capacity (Vc) (Bernstein RJ et al. 1996, Steenhuis LH et al. 2000). The decreased DL in 
association with decreased DM and Vc has been described in chronic heart failure patients 
in stable clinical condition (Agostoni P et al. 2006). There is also growing evidence that 
left ventricular diastolic function may become independently compromised in pulmonary 
artery hypertension (PAH) (Puwanant S et al. 2010 Tonelli AR et al. 2012). This may 
contribute to the reduced DL, DM, and Vc. In a recent study with PAH patients, findings 
indicated that lower than normal gas transfer in PAH is due to loss of both DM and Vc, 
but deterioration of DM/Vc over time is related to worsening membrane diffusion (Farha 
S et al. 2013). 
 
2.4 Prognostic stratification of PE  
 
Acute treatment of PE is planned in accordance with mortality risk based on prognostic 
stratification. Both ESC (European Society of Cardiology) and ACCP (American College 
of Chest Physicians) guidelines suggest evaluating treatment of PE according to clinical 
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risk (Kearon MB et al. 2008, Torbicki A et al. 2008). Risk markers useful for risk 
stratification can be classified into three groups: clinical markers (shock, hypotension), 
markers of RVD, and markers of myocardial injury. Clinical assessment based on these 
clinical markers allows stratification into high-risk and non-high-risk PE. Classification 
can be utilized in evaluating the choice of optimal diagnostic strategy and initial treatment 
(Torbicki A et al. 2008). High-risk patients need an immediate diagnostic and treatment 
strategy since the short-term mortality rate in this group is over 15% (Kasper W et al. 
1997). Non-high-risk patients are normotensive. As normotensive patients often present 
with RVD, non-high-risk PE patients can be further stratified according to the presence of 
RVD into intermediate- and low-risk PE (Torbicki et al. 2008). Moreover, accurate and 
objective models of prognosis could help clinicians to determine the appropriateness of 
early hospital discharge or complete ambulatory treatment for patients with acute 
symptomatic PE. The Pulmonary Embolism Severity Index estimates the risk of 30-day 
mortality in patients with acute PE. The Pulmonary Embolism Severity Index and its 
simplified version (Table 3) (Aujesky D et al. 2005, Jimenez D et al. 2010) can also be 
helpful in evaluating stratification on a clinical basis. 
 
Table 3. The Pulmonary Embolism Severity Index and its simplified version (modified from 
Aujesky D et al. 2005, Jimenez D et al. 2010). 
Variable Original PESI
a
Simplified PESI
b
Age > 80 years Age in years 1
Male sex +10
History of cancer +30 1
History of heart failure +10 1
c
History of chronic lung disease +10
Pulse ≥ 110 beats/min +20 1
Systolic blood pressure < 100 mm Hg +30 1
Respiratory rate ≥ 30 breaths/min +20
Temperature < 36°C +20
Altered mental status +60
Arterial oxyhemoglobin saturation level < 90% +20 1
Score
 
 
a) Total point score for a given patient is obtained by summing the patient’s age in years and the 
points for each predictor present. Scores correspond to the following risk classes: 65 or less, class 
I; 66 to 85, class II; 86 to 105, class III; 106 to 125, class IV; and more than 125, class V. Patients 
in risk classes I and II are defined as being at low risk. 
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b) Total point score for a given patient is obtained by summing the points. Scores correspond to 
the following risk classes: 0, low risk; 1 or more, high risk. Empty cells indicate that the variable 
was not included. 
c) Variables (history of heart failure and chronic lung disease) were combined into a single 
category of chronic cardiopulmonary disease. 
 
Different treatment procedures exist for patients with PE. High-risk patients (representing 
about 5% of all symptomatic patients) should be treated aggressively with thrombolytic 
agents or embolectomy (Kucher N et al. 2006). Low-risk patients (most patients with PE) 
might benefit from early discharge or even outpatient treatment (Aujesky D et al. 2011). 
Intermediate-risk patients (about 30% of all symptomatic patients) should probably be 
admitted to hospital and may benefit from thrombolytic agents. Recent results from the 
Hestia Study also suggest that certain APE patients could be selected for outpatient 
treatment with predefined criteria (Zondag W et al. 2011). For patients with low-risk PE 
and adequate home circumstances, early discharge was recommended in recent ACCP 
guidelines (Guyatt GH et al. 2012). 
Echocardiography or elevated levels of troponin or pro-brain natriuretic peptide might 
aid in prognostic stratification (Agnelli G et al. 2010, Goldhaber SZ et al. 2012). 
In recent years, studies involving multiple prognostic variables (so-called hybrid 
studies) demonstrate that combinations of RVD, elevated natriuretic peptides, or elevated 
troponin indicate adverse prognosis (Binder L et al. 2005, Kostrubier M et al. 2005, 
Scridon T et al. 2005, Hsu IT et al. 2006, Kline JA et al. 2006, Logeart D et al. 2007, 
Maziere F et al. 2007, Tulevski II et al. 2007, Jimenez D et al. 2008, Kline JA et al. 2008, 
Palmieri V et al. 2008, Bova C et al. 2009, Vuilleumier N et al. 2009). Although the 
techniques as described have utility for predicting prognosis in acute PE, clinical judgment 
is required to determine which of these is appropriate for each patient. American Heart 
Association (Jaff M et al. 2011) has proposed a definition for submassive PE: acute PE 
without systemic hypotension (blood pressure ≥90 mmHg) but with either RVD or 
myocardial necrosis. RVD refers to the presence of at least one of the following: 
1. RV dilatation (apical 4-chamber RV diameter divided by LV diameter >0.9) or RV 
systolic dysfunction on echocardiography 
2. RV dilatation (4-chamber RV diameter divided by LV diameter >0.9) on CT 
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3. Elevation of BNP (>90 pg/ml), elevation of N-terminal pro-BNP (>500 pg/ml) or 
electrocardiographic changes (new complete or incomplete right bundle-branch block, 
anteroseptal ST elevation or depression, or anteroseptal T-wave inversion) 
4. Elevation of troponin I (>0.4 ng/ml) or elevation of troponin T (>0.1 ng/ml) 
 
2.5 Treatment of VTE 
 
2.5.1 Acute treatment of VTE 
 
The goal of therapy for lower-extremity DVT is to prevent extension of thrombus and PE 
in the short term and to prevent recurrent events in the long term (Scarvelis D et al. 2006). 
The ACCP consensus statement on VTE recommends initial treatment with low 
molecular weight heparin (LMWH) subcutaneously once or twice daily as an outpatient if 
possible. Initiation of vitamin K antagonist is started on the same day. With unfractionated 
heparin (UFH) or LMWH, the dose should be weight-based. If there is a high clinical 
suspicion of DVT, treatment with anticoagulants should be initiated while awaiting the 
outcome of diagnostic tests. In selected patients with extensive acute proximal DVT 
(iliofemoral DVT, symptoms for < 14 days, good functional status, life-expectancy ≥1 
year) with low risk for bleeding, catheter-directed thrombolysis followed by balloon 
angioplasty and stents may be used to reduce acute symptoms and post-thrombotic 
morbidity. Initial treatment with LMWH, UFH, or the synthetic pentasaccharide 
fondaparinux is recommended to continue for at least 5 days and until the INR is ≥2.0 for 
over 24 h (Kearon C et al. 2008). 
Placement of an inferior vena cava filter in addition to anticoagulation therapy has not 
been found to prolong survival among patients with DVT. A retrievable filter is indicated 
when there is a contraindication to anticoagulation therapy (recent hemorrhage, impending 
surgery) in patients with newly diagnosed proximal DVT (Scarvelis D et al. 2006). In 
catheter-directed thrombolysis, thrombolytic drugs are delivered using catheter-based 
techniques to achieve a higher concentration in the venous thrombus, thereby enabling clot 
lysis with reduced thrombolytics (Semba CP et al. 1994, Vedantham S et al. 2006). The 
underlying veins are evaluated after thrombolysis by venography, and balloon angioplasty 
or stent placement is performed if needed. Limitations of the technique are the fairly long 
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infusion time required to lyze extensive DVT and the healthcare resources used (Popuri R 
et al. 2011). 
Systemic thrombolytic therapy has been shown to reduce the incidence of post-
thrombotic sequelae compared with anticoagulant therapy alone (Elliot MS et al. 1979, 
Arnesen H et al. 1982, Killewich LA et al. 1989). Whether early canalization results in 
lower rates of PTS in the long run remains unknown (Forster AJ 2001). Recently, 
catheter-directed thrombolysis has overtaken systemic thrombolysis. Data from the 
National Venous Registry and subsequent studies on the role of catheter-directed 
thrombolysis for treatment of acute lower-extremity DVT indicate that the technique is 
safe and effective (Semba PC et al. 1994, Mewissen MW et al. 1999, Mewissen MW 
2010).  
Daily use of graduated elastic compression stockings for 2 years after a proximal DVT 
has been reported in several trials to significantly reduce the rate of PTS (Brandjes DP et 
al. 1997, Prandoni P et al. 2004). For a patient who has had a symptomatic proximal DVT, 
the use of an elastic compression stocking is recommended. Compression therapy, which 
includes the use of bandages acutely, should be started as soon as feasible after 
commencing anticoagulant therapy and continued for a minimum of 2 years, longer if 
patients have symptoms of PTS (Kearon C et al. 2008). 
All PE patients should undergo rapid risk stratification. For patients with evidence of 
hemodynamic compromise, the use of thrombolytic therapy unless there are major 
contraindications owing to bleeding risk should be considered. In selected high-risk 
patients without hypotension who are judged to have a low risk of bleeding, 
administration of thrombolytic therapy is suggested as well. The decision to use 
thrombolytic therapy depends on the clinician’s assessment of PE severity, prognosis, and 
risk of bleeding (Kearon C et al. 2008). Thrombolytic therapy should not be used in 
patients with low-risk PE. Catheter embolectomy or fragmentation of proximal pulmonary 
arterial clots may be considered in high-risk PE patients if thrombolysis is contraindicated 
or has failed (Torbicki et al. 2008). 
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2.5.2 Duration of anticoagulation 
 
The duration of anticoagulation has been debated for years. ACCP, AHA (American 
Heart Association), and ESC have each published their own guidelines, which are mainly 
in line with each other. 
For patients with DVT secondary to a transient (reversible) risk factor, ACCP 
guidelines recommend anticoagulation for 3 months rather than treatment for shorter 
periods. For patients with unprovoked DVT, anticoagulation is recommended for at least 3 
months. All patients with unprovoked DVT should be evaluated for the risk-benefit ratio 
of long-term therapy. For patients with a first unprovoked VTE that is a proximal DVT, 
for whom risk factors for bleeding are absent and for whom good anticoagulant 
monitoring is achievable, long-term treatment is recommended. For patients with PE and 
cancer, LMWH is recommended for 3-6 months as long-term anticoagulant therapy. For 
these patients, anticoagulant therapy is recommended indefinitely or until the cancer is 
resolved. If the patient has a second episode of unprovoked VTE, long-term 
anticoagulation should be considered (Kearon C et al. 2008). The length of the 
anticoagulation therapy depends on the patient’s VTE risk factors, presence of recurrent 
VTE, bleeding risk factors, and the patient’s opinion (Prandoni P et al. 1996, Heit IA et al. 
2000). 
D-dimer is an indirect marker of residual thrombosis (Bockenstedt P 2003). In a 
systematic review of patients with a first episode of unprovoked VTE, a negative D-dimer 
after a 2-year follow-up was associated with a 3.5% annual risk for recurrent disease, 
whereas a positive D-dimer result was associated with an 8.9% annual risk (Verhovsek M 
et al. 2008). These results were confirmed in a systematic review (Douketis J et al. 2010). 
In the multicenter, prospective PROLONG study, patients with an abnormal D-dimer level 
one month after the discontinuation of anticoagulation had a significant incidence (15%) 
of recurrent VTE (Palareti G et al. 2006). These findings suggest that D-dimer assay may 
have a role when determining appropriate duration of anticoagulation. 
The therapeutic effectiveness and safety of warfarin depends on maintaining the 
international normalized ratio (INR) in the therapeutic range. Because of the dose 
response variability and interactions with drugs and diet, warfarin therapy can be 
troublesome and time-consuming to manage (Ansell J et al. 2008). Most patients are 
treated with oral warfarin as a first-line long-term anticoagulant with initial LMWH 
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therapy for a minimum of 5 days and until INR is ≥2.0 for at least 24 h (Hull R et al. 1979, 
Levine MN et al. 1995, Kearon C et al. 2003, Ridker PM et al. 2003). 
A number of new oral anticoagulants are currently under evaluation (Mavrakanas T et 
al. 2011). These orally administered direct inhibitors of FXa (rivaroxaban, apixaban) or 
thrombin (dabigatran) avoid most of the drawbacks of heparin and require no dose 
monitoring. In certain situations, it could be beneficial to monitor their effects such as in 
the case of suspected overdose, patients who need emergency surgery, or patients with a 
thromboembolic or hemorrhagic event (Lindhoff-Last E et al. 2010, Samama M et al. 
2011). Dabigatran has been shown to be as safe and effective as warfarin for acute VTE 
(Schulman S et al. 2009, Einstein Investigators 2010). Rivaroxaban was the first drug to 
be accepted for the treatment of VTE. It is expected that other new oral anticoagulants, 
such as dabigatran, apixaban, and edoxaban, will be available in the near future, as the 
final phases and results of clinical trials are completed (Agnelli G et al. 2013, Schulman S 
et al. 2011, Schulman S et al. 2013, Raskob G et al. 2013). The major problem/drawback 
with these new drugs is the lack of an effective antidote and the lack of long-term 
experiences. However, these newer anticoagulants have shorter half-lives and the need for 
reversal agents is less critical. In healthy volunteers, a four-factor prothrombin concentrate 
was effective in reversal of rivaroxaban activity (Eerenberg E et al. 2011). Recent 
preclinical studies have shown promise for agents in the reversal of anticoagulant activity 
(Zhou W et al. 2011). Administration of prothrombin complex concentrate or activated 
prothrombin complex concentrate may be considered in addition to supportive measures 
for patients with severe or life-threatening bleeding. Target-specific antidotes are being 
developed, but require further investigations (Siegal DM et al. 2013). 
 
2.6 Long-term sequelae and follow-up of VTE  
 
2.6.1 Post-thrombotic syndrome (PTS) 
 
Approximately two-thirds of patients with ileofemoral DVT will develop post-thrombotic 
syndrome (Strandness D et al.1983, Landefeld CS 1993, Branjes DP et al. 1997). PTS is 
characterized by leg swelling, pain, darkened skin color, and sometimes ulcers. 
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Manifestation of PTS becomes apparent within 1-5 years after acute thrombosis, in most 
patients within the first 2 years (Prandoni P et al. 1996, Brandjes DP 1997). 
Diagnosis of PTS is mainly based on clinical findings for patients with a history of 
DVT. Villalta PTS scale (Villalta S 1994) and the CEAP (clinical, etiologic, anatomic, and 
pathophysiologic) classification for chronic venous disease (Porter JM et al. 1995) are 
frequently used to measure PTS in clinical practice. 
When carefully supervised and proper elastic compression stockings are worn, more 
than 50% of patients either remain quiescent or improve during long-term follow-up 
(Pesavento R et al. 2010). The placement of iliac vein stents to reduce PTS symptoms and 
heal venous ulcers in patients with advanced PTS can be considered. The adequacy of 
anticoagulation treatment therapy should be evaluated as well (Jaff M et al. 2011). Clinical 
predictors of PTS are proximally extensive DVT, prior ipsilateral DVT, persistent venous 
symptoms one month after DVT, obesity, and older age. The likelihood of developing 
PTS after DVT should be discussed with patients, and symptoms and signs of PTS should 
be monitored during clinical follow-up (Kahn SR et al. 2009). 
 
2.6.2 Chronic thromboembolic pulmonary hypertension (CTEPH) 
 
Pulmonary hypertension is a hemodynamic and pathophysiological condition that is 
defined as an increase in mean pulmonary arterial pressure ≥25 mmHg at rest, as assessed 
by right heart catheterization (Galie N et al. 2009). 
CTEPH is a late complication of PE. The natural history of most emboli is to undergo 
total or almost total resolution with restoration of normal pulmonary hemodynamics 
(Moser KM et al.1990). In patients with CTEPH, the original embolic material is replaced 
over a period of months to years with fibrous tissue. This material may extend from the 
main pulmonary trunk to the segmental and subsegmental branches of the pulmonary 
arteries. Partial recanalization or total occlusion of the involved pulmonary artery 
vasculature may occur (Moser KM et al. 1990, Galie N et al. 2009). The consequence is an 
increased pulmonary vascular resistance, resulting in pulmonary hypertension and right 
heart failure (Hoeper MM et al. 2006). 
Follow-up studies have detected RVD in 6-20% of patients (Kline JA et al. 2009, 
Golpe R et al. 2010). Pengo V et al. (2004) reported symptomatic CTEPH in 4% of 
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patients 2 years after the first episode of symptomatic pulmonary embolism. Thus, the 
occurrence of CTEPH is not rare. 
Patients with a history of DVT or PE who present with dyspnea, exercise intolerance, 
or clinical evidence of right heart failure should undergo diagnostic evaluation for CTEPH 
(Jaff R et al. 2011). The diagnosis of CTEPH is based on echocardiography, perfusion 
scintigraphy, CT, right heart catheterization, and pulmonary angiography (Coulden R et al. 
2006). Medical therapy aims to treat right heart failure and to lower pulmonary artery 
resistance. The efficacy of the medical therapy is limited by the morphological substrate of 
pulmonary artery obstruction. Pulmonary endarterectomy has provided fairly good results. 
Drugs targeting the pulmonary circulation of patients in whom surgery is not possible or 
has failed are undergoing clinical trials (Torbick A et al. 2008). CTEPH patients should 
receive lifelong anticoagulation to prevent recurrence of thromboembolic events (Hoeper 
MM et al. 2006). 
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3. AIMS OF THE STUDY 
 
 
 
The main purpose of this study was to determine the easiest way to diagnose right 
ventricular dysfunction in emergency department acute non-high-risk patients and to 
identify those patients likely to benefit from follow-up. A further aim was to evaluate the 
long-term clinical outcome of patients with earlier PE or DVT. 
 
Specific aims of the four studies were as follows: 
 
1. To develop a sensitive, fully quantitative and automated POC testing assay for D-dimer 
in whole blood with the shortest possible assay time. 
2. To determine the value of CT and NT-proBNP in detection of right ventricular 
dysfunction in the acute phase and during follow-up of non-high-risk acute pulmonary 
embolism in clinical practice. 
3. To study the membrane and pulmonary capillary blood volume components of diffusing 
capacity at the acute stage of pulmonary embolism to determine which parameters are 
associated with right ventricular overload.  
4. To compare the reflux patterns in patients with iliofemoral venous thrombosis 2-3 years 
after systemic or catheter-directed thrombolysis. 
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4. PATIENTS AND METHODS 
 
 
 
Study I: Rapid measurement for D-dimer in VTE patients 
 
This prospective study comprised patients (n=525) from the University Central Hospitals 
of Helsinki, Turku, and Kuopio. The diagnoses for DVT and PE were performed with 
duplex ultrasound examination and helical-CTscan according to accepted protocols in 
clinical use. Samples from age-adjusted healthy volunteers (n=101) were collected among 
the staff at the Department of Biotechnology, University of Turku, and at Innotrac 
Diagnostics, Turku, Finland. 
All whole-blood samples were analyzed fresh, and plasma samples were analyzed 
either fresh or stored frozen at –20°C or –70°C until use. The samples were stable at both 
freezing temperatures. The simple, automated assay procedure comprises a 1:50 sample 
dilution, one-step incubation, washing, and time-resolved fluorometric measurement 
directly from the wet well surface. The Roche Diagnostics TinaQuant ® D-Dimer (Knecht 
MF et al. 1997) and the Biopool Auto Dimer® (Bozic M et al. 2003) assays were used as 
comparison methods. A cut-off value of 0.5 mg/l was employed in both methods. 
Commercial D-dimer control preparations were purchased from Bio-Rad Laboratories and 
from Biopool and were used as instructed by the manufacturers. 
The study protocol was approved by the Ethics Committee of Helsinki University 
Central Hospital, and written informed consent was obtained from all participants. 
 
 
Study II: Right ventricular overload in patients with acute pulmonary 
embolism: role of helical computerized tomography (CT) and N-terminal 
pro-BNP in screening and follow-up in routine patient care 
 
This was a single-center prospective follow-up study carried out at the Emergency 
Department of Helsinki University Central Hospital between January 2003 and August 
2004. Sixty-three consecutive patients were included in the study. The main inclusion 
PATIENTS AND METHODS 
34 
 
criterion was CT-confirmed APE. Subjects with massive APE (hemodynamically unstable 
patients), pulmonary disease with regular medication, previous APE, ongoing 
anticoagulation therapy, and end-stage cancer (estimated life-expectancy of less than 7 
months) were excluded. No randomization of treatment was performed. Management of 
patients was decided by the clinician in charge. 
On admission, right ventricular overload was assessed by the following four different 
methods: 1) CT, 2) TTE, 3) cardiac biomarkers (NT-proBNP and cardiac troponin T), and 
4) clinical evaluation including ECG. TTE, cardiac biomarkers, and clinical evaluation 
were repeated 7 months later. A detailed medical history, including risk factors for 
thromboembolic events (age, gender, immobilization (within 3 months), hormone 
replacement or contraception therapy, family history of venous thromboembolic events, 
active cancer, varicose veins, smoking, weight, and height), was collected from all 
patients. Patient characteristics and risk factors are presented in Table 4. 
 
Table 4. Characteristics and risk factors of 63 patients. 
Parameter Patients, n (%)
Age  >75 years 10 (16)
Gender
    Male 30 (48)
    Female 33 (52)
BMI (Body Mass Index) >25 kg/m2 50 (79)
Immobilization 28 (44)
(prolonged immobility, hospitalization, surgery within 3 months) 
Hormone therapy 13 (21)
(Hormone replacement therapy n=7)
Contraception n=6
History of DVT* 7 (11)
Family history of VTE** 5 (8)
Thrombophilias*** 9 (14)
Homocysteinemia ( > 12μmol/l) 11 (17)
Active cancer 3 (5)
Varicose veins 27 (43)
Diabetes mellitus 5 (8)
Asthma (mild, no regular medication) 5 (8)
Smoking
    Smokers 11 (17)
    Ex-smokers 19 (30)
    Non-smokers 33 (52)  
* DVT= Deep venous thrombosis 
** VTE= Thromboembolic disease 
*** Known previously or detected in clinical laboratory tests 
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Blood samples for plasma NT-proBNP, cardiac troponin T (cTNT), and D-dimer were 
collected at presentation. D-dimer >0.5 mg/l and cTNT >0.03 ug/l were assessed as 
abnormal. NT-proBNP value ≥350 ng/l was regarded as elevated. The criteria of RVD in 
CTPA were RV/LV ratio over 1.0 and/or deviation (straightening or bowing) of the 
interventricular septum (Schoepf UJ et al. 2004, Araoz PA et al. 2003).The diameters of 
the ventricles were measured on the axial image where the ventricles were the most 
distorted. Thirty-six CT examinations were performed with an 8-slice scanner (GE Light 
Speed Ultra), 22 with a 4-slice scanner (22 with Philips Mx 8000, one with GE High 
Speed), and 5 with a single-slice scanner (GE High SpeedLX/i).  
TTE was performed within 24 h of the diagnosis of APE using the Vivid Digital 
Ultrasonography System (GE Vivid 5 or Vivid 7, Horten, Norway). Recordings were 
stored on an M-mode, two-dimensional color-flow disc, and Doppler data were stored on a 
magneto-optic disc. Examination was performed both in a left lateral and in a flat supine 
position. All studies were performed by experienced cardiologists blinded to the results of 
biochemical assays. TTE was repeated 7 months later by the same cardiologist as on 
admission. Presence of RVD was assessed using the following established criteria: 1) 
increased ratio of RV and left ventricular end-diastolic diameter (RV/LV) above 0.9, 2) 
presence of paradoxical septal wall motion, and 3) mean peak velocity greater than 2.8 
m/s. At least one of these criteria had to be positive. 
All statistical analyses were performed with SPSS 15.0 for Windows (SPSS Inc., 
Chicago, IL, USA). The subjects were categorized into two groups: RVD positive and 
RVD negative. Data are presented as frequencies or percentages for categorical variables 
and as mean (SD) for continuous variables, unless otherwise noted. Normality of 
continuous variables was checked by the Kolmogorov-Smirnov test. Between-group 
differences were assessed by the Mann-Whitney U-test. Categorical data were compared 
by the Chi-square test or Fischer´s exact test. P-values <0.05 were considered statistically 
significant. 
The study protocol was approved by the Ethics Committee of Helsinki University 
Central Hospital, and written informed consent was obtained from all participants. 
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Study III: Reduction of membrane component of diffusing capacity is 
associated with the extent of acute pulmonary embolism 
 
Forty-seven consecutive patients (24 women, 23 men) with acute non-high-risk PE 
confirmed by computerized tomography (CT) at the Emergency Department of Helsinki 
Meilahti University Central Hospital were enrolled in the study. Patients were recruited 
between January 2003 and August 2004. Exclusion criteria comprised clinically massive 
PE (hemodynamically unstable patients), chronic pulmonary disease requiring regular 
medication, previous PE, anticoagulation therapy, and terminal cancer (with estimated 
life-expectancy of less than 7 months). In addition, patients arriving at the hospital 
between Friday 18:00 and Sunday 12:00 were excluded because the services of the 
laboratory of clinical physiology were unavailable at that time. The measurements of DL, 
CO with DM and Vc were scheduled within 24 h of diagnosis of PE. DL, CO, Vc, DM, 
and VA were measured by using the single breath method with carbon monoxide and 
oxygen (Viljanen AA 1982) applying the European Respiratory Society recommendations 
(McIntyre N et al. 2005) at both the acute phase and 7 months later. The measurements 
were done with Jaeger MasterScreen PFT equipment (Würzburg, Germany). Values of 
diffusing capacity were corrected with actual hemoglobin concentration in blood. Flow-
volume spirometry was performed at the 7-month control to exclude patients with 
pulmonary obstruction. At the acute phase, spirometry was not performed for safety 
reasons. Forced vital capacity (FVC), forced expiratory volume in one second (FEV1), 
and forced expiratory flow at a level where 50% of FVC remains to be exhaled (MEF50) 
were recorded. 
The extent of PE was assessed by scoring mass of embolism. Mass of embolism was 
calculated using the method of Mastora (Mastora I et al. 2003), in which CT severity score 
is based on the percentage of the obstructed surface of each central and pulmonary arterial 
section using a 5-point scale. Echocardiography was also performed. Patients were given 
antithrombotic treatment according to guidelines in force at the time of the study. Most of 
the patients were treated initially with low molecular weight heparin, followed by warfarin 
for 6 months. Seven months later, diffusing capacity measurements were repeated and 
flow-volume spirometry was performed. Echocardiography was also repeated to identify 
patients with RVD. Fifteen healthy, age-matched controls (9 women, 6 men) were also 
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studied; for 12 of them (three did not come to the second measurement), the measurements 
were repeated later, at times corresponding to those of the patients. 
Lung function parameters were compared between patients and controls with 
independent samples t-test. Correlation methods were used to determine the covariants, 
and analysis of covariance (ANCOVA) was applied to adjust the results according to 
covariants. For parameters indicated as percentages of predicted values, the results were 
adjusted for years and also for weight if weight was not calculated in the reference value; 
for parameters indicated as absolute values, the results were adjusted for height, weight, 
age, and smoking. In multiple comparisons, Bonferroni correction was used. 
Partial correlation was used to adjust the lung function parameters for age, height, 
weight, and smoking. 
 
Table 5. Gender and anthropometric data of patients with PE and healthy control subjects. 
Patients with PE Healthy controls Singificance in t-test
Gender, male/female (persons) 23/24 6/9
Weight (kg) 88.9 (18.1) 73.0 (11.2) 0.002
Height (cm) 172.0 (10.4) 173.0 (11.1) 0.730
Age (years) 56.1 (16.3) 55.0 (16.5) 0.881
Smoking (pack-years) 3.92 (7.6) 2.67 (6.0) 0.469
Number (percent) of 30 (63.8) 11 (73.3)
non-smokers 7 (14.9) 2 (13.3)
smokers 10 (21.3) 2 (13.3)
ex-smokers
0.761 *
 
* Chi-square test 
 
The change in the parameters during follow-up was analyzed with paired t-test, or with 
Wilcoxon’s pairwise test when the variable was not normally distributed. To evaluate the 
influence of lung volume on the observed changes, the difference in VA between the acute 
and recovery phases of PE was compared in regression analysis with the corresponding 
difference in DL, CO, DL, CO/VA, DM, or Vc between the examination phases. SPSS 
Windows version 15.0 was used in all calculations. 
The study protocol was approved by the Ethics Committee of Helsinki University 
Central Hospital, and written informed consent was obtained from all participants. 
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Study IV: Comparison of venous valve function after catheter-directed 
and systemic thrombolysis for deep venous thrombosis 
 
Patients with ileofemoral deep venous thrombosis treated with either systemic or catheter-
directed thrombolysis were evaluated in this retrospective study 2-3 years after the 
thrombotic event. A total of 60 patients with a diagnosis of deep iliofemoral DVT were 
collected from the Helsinki University Central Hospital Emergency Care Data Registry 
over a one-year period, from July 1999 to the end of June 2000. Of 60 patients, 12 had 
died since the acute event and 11 were treated with low molecular weight heparin and 
anticoagulation without thrombolysis. Altogether 37 patients treated with thrombolytic for 
ileofemoral DVT participated in the study. The patients had overt clinical signs and 
symptoms of DVT, and the initial diagnosis had been established with compression two-
dimensional B-mode ultrasound. Of the 37 patients, 16 had been treated with catheter-
directed thrombolysis with recombinant tissue plasminogen activator (rt-PA) and 16 with 
systemically administered thrombolysis either with streptokinase or rt-PA. Furthermore, 
there were 5 patients who received catheter-directed thrombolysis after an initial systemic 
thrombolysis had failed to produce an adequate clinical result. This group of 5 patients 
was not included in the final analysis because of its small size. The study sample thus 
included 32 patients. Three of the 16 patients in the catheter-directed lysis-treated group 
had residual stenosis after lysis and were treated with percutaneous balloon angioplasty 
(PTA) (1 patient), PTA and stenting (1 patient), and catheter thrombectomy (1 patient). 
All patients also received treatment with low weight molecular heparin and 
anticoagulation. 
The clinical status of the affected leg was classified from 0 to 6 according to the 
clinical, etiologic, anatomic, and pathophysiologic (CEAP) classification (Rutherford RB 
et al. 2000, Porter J et al. 1995), and disability score was calculated at follow-up 2-3 years 
after the acute event. A detailed systemic examination of the entire venous system from 
the groin to the ankle was performed for the limb with previous DVT by an experienced 
vascular surgeon who was blinded to the previous treatment. Reflux was assessed with 
color duplex ultrasound (Hewlett Packard M2410A scanner using 5 MHz probe), and 
standardized distal pneumatic cuff release (Venopulse, STR Teknik, Norway) was used to 
provoke venous reflux. 
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Patients were also asked to fill in the questionnaire concerning risk factors, duration of 
anticoagulation therapy, and use of compression stockings. No significant baseline 
difference between these two groups was found (Table 6). 
 
Table 6. Patient characteristics. 
Variables
CATHETER-DIRECTED 
LYSIS
SYSTEMIC 
LYSIS
No. of patients 16 16
No. of males 8 6
Age (years)  mean and range 56 (21 to 86) 61 (35 to 81)
Thrombus age (days) mean and range 3 (1 to 8) 4 (1 to 14)
Thrombolytic agents      
      Alteplase (n) 16 4
      Streptokinase (n) 0 14
Total dose of thrombolytic 
      Alteplase (mg)   mean and range 73 (20 to 142)
229 (100 to 
343)
      Streptokinase (IU) mean and range
6.5x106 (2.7 to 
7.4x106)
Duration of thrombolytic therapy (hours) mean and range 33 (12 to 72) 62 (33 to 72)
Bleeding
      Major 13% (2/16) 6% (1/16)
      Minor  25% (4/16) 38% (6/16)
      Intracranial haemorrhage 0 0
Concomitant pulmonary embolism 13% (2/16) 31% (5/16)
Genetic risk factor 25% (4/16) 13% (2/16)
Risk factors * 50% (8/16) 75% (12/16)
Use of compressing stockings 50% (8/16) 38% (6/16)
Warfarin treatment 
      Permanent warfarin usage 38% (6/16) 38% (6/16)
      Duration of warfarin (months) mean and range 8 (3 to 24) 8 (3 to 15)  
* Presence of one or more of the following risk factors: genetic thrombophilias, previous deep 
venous thrombosis or pulmonary embolism, obesity, hormones, smoking, surgery, traveling, 
immobilization in the 3-month period before onset. 
 
Statistical measurements were made with the 2 method with no continuity correction. 
Statistical significance was defined as a P-value of less than 0.05 
The study protocol was approved by the Ethics Committee of Helsinki University 
Central Hospital, and written informed consent was obtained from all participants. 
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5. RESULTS 
 
 
 
Study I: Rapid measurement of D-dimer in VTE patients 
 
The analytical detection limit of the assay, calculated as the mean background signal +3 
SD, was 0.046 mg/l. The within- and between-assay imprecision was similar for whole-
blood and plasma samples, ranging from 8.3% to 13% below and from 3.8% to 7.7% 
above the cut-off level of 0.6 mg/l. The estimate of 0.2 mg/l for the limit of quantification 
appeared to be correct also based on the precision studies. The within- and between-assay 
imprecision was also calculated for commercial D-dimer controls from Bio-Rad and 
Biopool and showed a corresponding imprecision. Measurable concentrations of D-dimer 
were found in most citrated blood samples taken from apparently healthy volunteers. Both 
the whole-blood and plasma fractions were measured, and the results obtained in whole 
blood were corrected for the individual’s hematocrit values. For persons <50 years of age 
(n=66), the median D-dimer concentrations were 0.19 and 0.24 mg/l in whole blood and 
plasma, respectively, with the highest measured concentrations of 0.51 and 0.57 mg/l. The 
upper reference limits based on the 95
th
 percentile were 0.41 mg/l in whole blood and 0.45 
mg/l in plasma. For individuals ≥50 years of age (n=35), however, the reference values 
were notably higher. The median values for this age group were 0.36 mg/l in both whole 
blood and plasma, with the highest measured concentrations of 1.0 and 0.93 mg/l. The 
upper reference limits based on the 95
th
 percentile were 0.84 and 0.82 mg/l in whole blood 
and plasma. In the entire population of apparently healthy volunteers (n=101), the median 
D-dimer concentrations in whole blood and plasma were 0.24 and 0.29 mg/l, with upper 
reference limits (95
th
 percentile) of 0.68 and 0.56 mg/l. The 10-min D-dimer assay was 
compared with the Roche Diagnostics TinaQuant
 
D-dimer assay. 
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Table 7. Characteristics of the 10-min D-dimer assay using two different clinical decision limits 
(mg/l cut-offs). 
0.6 mg/l 1.0 mg/l
Sensitivity (95% CI), % 98.7 (93.0 – 100.0) 92.2 (83.8 – 97.1)
Specificity (95% CI), % 64.4 (56.8 – 71.5) 81.0 (74.4 – 86.6)
NPVa, % 99.1 95.9
PPVb, % 55.1 68.3
Test efficiencyc, % 74.9 84.5
Cut-off value
 
a
NPV=negative predictive value
 
b
PPV=post-predictive value 
 
Of the 77 samples obtained from patients with DVT and/or PE, all but one (which was 
negative in the Tina Quant assay as well) gave a result above the cut-off level of 0.6 mg/l 
(98.7%), and 71 (92.2%) gave a result ≥1.0 mg/l; the median D-dimer value of the whole 
group was 6.67 mg/l.  However, although the median D-dimer level in the group of 
unselected outpatients with a wide range of other diseases was only 0.43 mg/l (n=174), a 
significant portion of these samples were above the cut-off levels of 0.6 mg/l (62 samples, 
35.6%) and 1.0 mg/l (30 samples, 17.2%), demonstrating the low specificity of the assay 
in a typical outpatient population. The reasons for the increased D-dimer concentrations 
included cardiovascular disease (n=7), kidney disease (n=6), atrial fibrillation (n=5), 
erysipelas (n=4), cancer (n=4), pneumonia (n=2), hepatitis (n=1), other 
infection/inflammatory disease (n=7), other thrombotic disorder (n=6), and multiple 
concurrent diseases (n=4); the reason was unknown or unreported in 16 cases. 
 
 
Study II: Right ventricular overload in patients with acute pulmonary 
embolism: role of helical computerized tomography (CT) and N-terminal 
pro-BNP in screening and follow-up in routine patient care 
 
Right ventricular overload was detected with CT in 37 (59%) of 63 patients (Figure 2). 
Twenty-eight patients (76%) in the RVD-positive group also had signs of RVD in TTE 
performed within 24 h of the diagnosis. Nine of the RVD-positive patients (24%) showed 
no echocardiographic alterations in RV morphology or function. Overall, findings of RVD 
in CT were congruent with those of echocardiography (p<0.0001). Findings suggesting 
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RVD were found with TTE in three of the initially RVD-negative patients. These patients 
had as the only sign of RVD mean tricuspid regurgitation peak velocity of 2.9-3.1 m/s. 
 
Figure 2. Evaluation of right ventricular dysfunction with CT 
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Recruited to the study
(n= 63)
Investigated for APE
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The RVD diagnosis was based on both right ventricular and left ventricular ratio, and 
septum deviation was detected in most (73%) of the patients. Detailed information of 
RVD findings in CT of these 37 RVD patients is presented in Table 8. 
 
Table 8. CT findings of RVD patients and elevated pro-BNP in the criteria groups. 
CT findings pro-BNP over 350 ng/l 
n (%)                   n=37 n (%)             n=32
RV/LV >1 (only) 3 (8.1)  2 (66.7)
septum deviation (only) 7 (18.9)  6 (85.7)
RV/LV >1 and septum deviation 27 (73.0)   24 (88.9)  
RV= right ventriculum 
LV= left ventriculum 
 
Of patients who had RVD in CT, 32 (86%) also had NT-proBNP ≥350 ng/l, whereas in 7 
patients (27%) with no RVD NT-proBNP was over the limit (p<0.0001). TnT was above 
RESULTS 
43 
 
the reference value in 11 (17%) of 63 patients; 9 (82%) of these patients were RVD-
positive and 2 (18%) were RVD-negative (p<0.082). At the 7-month follow-up, RVD was 
detected in 6 (10%) of 63 patients. These patients also had elevated NT-proBNP levels (p< 
0.0001). All patients who were found to have persistent RVD had RVD in both CT and 
TTE on admission. 
Signs of RV overload in admission ECG were detected in 33 patients. In the RVD-
positive group, 32 (86.5%) of 37 patients had signs of RVD in ECG, whereas 8 patients 
(13%) had such findings in the RVD-negative group (p<0.0001). Findings of ECG (one or 
more) are presented in Table 9.  
 
Table 9. Electrocardiogram (ECG) in APE patients 
Criteria of ECG changes Total RVD-positive RVD-negative
Sinus tachykardia (pulse rate > 100/min) 9 7 2
T-wave inversion in leads V1-V3 26 20 6
Complete or incomplete right bundle branch block 4 3 1
S1Q3T3 configuration 3 1 2
P-pulmonale 1 1 0  
 
Arterial hypoxemia was detected in 56 (93%) and hypocapnia in 27 (45%) of 60 
patients. RVD-positive patients (n=37) had significantly more often hypoxia and 
hypocapnia (n=36) than patients in the RVD-negative group (p<0.0001). Elevated D-
dimer levels were detected in all 63 patients. The levels of D-dimer did not differ between 
the RV-positive and RV-negative groups (p<0.102). 
 
 
Study III: Reduction of membrane component of diffusing capacity is 
associated with the extent of acute pulmonary embolism 
 
The total score for mass of embolism varied between 0 and 110 (mean, SD; 54.1, 32.4), 
corresponding to a 0-71% obstruction of the total pulmonary artery bed. Forty patients had 
both central and peripheral emboli. Seven patients had only peripheral emboli and one 
subsegmental emboli. The score for central mass of embolism was 0-34 (mean, SD; 17.5, 
1.8), corresponding to a 0-62% obstruction of the central pulmonary artery bed. The scores 
for peripheral mass of embolism ranged from 0 to 82 (37.0, 22.5), thus, a 0-82% 
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obstruction of the peripheral pulmonary artery bed. 
DL, CO, Vc, DM, and VA were lower in patients with acute PE than in healthy 
controls (p<0.001). DM correlated inversely with central mass of embolism (r=-0.312; 
p=0.047), whereas Vc did not. 
DM, DL, CO, VC, and VA improved significantly within 7 months. It is notable that in 
all patients (p=0.001, p=0.001), also persistent RVD patients (p= 0.020, p=0.012), DM, 
DL, and CO remained significantly lower than in healthy controls at follow-up. DM was 
inversely related to central mass of embolism. Reduction in DM mainly explains the 
sustained decrease in DL and CO in PE after 7 months despite modern and adequate 
treatment of PE (Table 10). 
 
Table 10. Lung function data of patients and healthy controls during the acute phase and at the 7-
month follow-up. 
Variable Patients, 
acute 
phase, 
n=47
Controls, 
acute phase, 
N=15
Significance 
between 
patients and 
controls, 
acute phase 
# **
Patients, 7 
month 
follow-up, 
n=47
Significance, 
patients 
acute vs. 7 
month follow-
up        ##
Controls, 7 
month follow-
up N=12
Significance 
between 
patients and 
controls, 7 
month follow-
up #**
VC (l) 3.5 (1.1)* 4.4 (1.1) <0.001 3.80 (1.19) < 0.001 4,25 (1.17) < 0.001
VC (%) 83.3 (15.5) 103.9 (14) <0.001 90.3 (16.4) < 0.001 104.1 (15.2) 0.062
VA (l) 4.3 (1.1) 5.5 (1.3) <0.001 4.7 (1.2) < 0.001 5.1 (1.15) < 0.001
DLCO (mmol/min/kPa) 5.9 (1.8) 8.3 (2.5) <0.001 6.6 (2.1) < 0.001 8.2 (2.5) < 0.001
DLCO (%) 73.7 (13.6) 103.7 (15.2) <0.001 82.3 (14.4) <0.001 101.1 (15.59 < 0.001
DLCO/VA (mmol/min/kPa/l) 1.39 (0.2) 1.48 (0.2) 0.259 1.30 (0.24) 0.568 1.47 (0.27) < 0.001
DLCO/VA (%) 94.6 (14.5) 104.4 (13.7) 0.025 96.3 (14.4) 0.278 104.8 (17.2) 0.023
Dm (mmol/min/kPa) 9.1 (3.0) 13.9 (4.7) <0.001 10.3 (3.8) 0.001 13.6 (4.9) < 0.001
Dm (%) 49.3 (15.6) 72.3 (22.8) <0.001 55.0 (19.3) 0.003 71.7 (28.7) 0.014
Qc (ml) 53.6 (16.1) 63.9 (22.6) <0.001 56.6 (16.5) 0.159 69.3 (19.5) < 0.001
Qc (%) 68.7 (17.2) 79.3 (19.4) 0.047 72.0 (16.5) 0.173 85.8 (18.1) 0.041
Dm/Qc relation 0.18 (0.09) 0.22 (0.06) 0.116 0.19 (0.09) 0.770 0.21 (0.11) 0.250
 
* Means and standard deviations are presented. 
**Level of significance according to Bonferroni correction is 0.004. 
# non-paired ANCOVA 
## paired ANCOVA 
 
At 7 months, the size and function of the right ventricle had normalized in most patients 
with RVD at baseline (24/47, 51%), but 5/47 patients (10.6%) still had RVD in 
echocardiography. In patients with persistent RVD at 7 months, DM was significantly 
lower than in those without RVD or in healthy controls. Also DL and CO remained 
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significantly lower in those with RVD than in healthy controls. In patients with permanent 
RVD, the correlations between VA and DL, CO, DL, CO/VA, DM, or Vc were not 
significant. 
 
 
Study IV: Comparison of venous valve function after catheter-directed 
and systemic thrombolysis for deep venous thrombosis  
 
In this non-randomized retrospective study of both catheter-directed and systemic 
thrombolysis-treated patients, 38% were using warfarin permanently at the follow-up visit. 
In the rest of the patients in both groups, the mean duration of warfarin treatment was 8 
months. 
Risk factors, including genetic defects, were found in 50% of catheter-directed and 
75% of systemic-treated patients (p=0.25). Fifty percent of the catheter-directed lysis 
patients and 38% of the systemic lysis-treated patients had used or were still using 
compression stockings (p=0.41). 
Valvular competence was preserved in 44% of patients treated with catheter-directed 
thrombolysis compared with 13% of those treated systemically (p=0.01). Any deep reflux 
was present in 44% of catheter-directed lysis-treated patients compared with 81% of 
systemic-treated patients (p=0.03). Any superficial reflux was observed in 25% and 63% 
of the patients, respectively (p=0.03). No significant differences emerged in other 
variables (Figure 3). 
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Figure 3. Anatomic distribution of refluxing venous segments after deep vein thrombosis in 
patients treated with catheter-directed thrombolysis (black column) or systemic thrombolysis (light 
gray column). 
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Patients treated with catheter-directed thrombolysis were recorded to have better clinical 
status at follow-up (Table 11). 
 
Table 11. Clinical classification at follow up. 
n % n  %
C0 7 44 2 13
C1 2 13 1 6
C2 1 6 2 13
C3 3 19 6 38
C4 3 19 5 31
C5 0 0 0 0
C6 0 0 0 0
Clinical class * Catheter-directed thrombolysis Systemic thrombolysis
*C0 = No visible signs of venous disease, C1 = Teleangiectases or reticular formation, C2 = 
Varicose veins, C3 = Edema, C4 = Skin changes, C5 = Skin changes + healed ulcer, C6 = Skin 
changes + active ulcer 
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6. DISCUSSION 
 
 
 
General view and summary of results 
 
This thesis includes a sample of VTE patients who underwent clinical, radiological, or 
biochemistry evaluation over the course of their illness. The main results of the four 
studies are as follows: 
1. The rapid and sensitive 10-min immunofluorometric D-dimer assay showed utility in 
rapid exclusion of VTE in outpatients. 
2. CT proved to be a valuable and sensitive imaging method to detect RVD in APE. RVD 
was detected in 37 (59%) of the patients with non-high-risk APE. Of patients who had 
RVD in CT, 32 (86%) also had NT-proBNP ≥350 ng/l, whereas in 7 patients with no RVD 
(27%) NT-proBNP was over the limit (p<0.0001). At the 7-month follow-up, RVD was 
detected in 6 (10%) of 63 patients, and all of these patients also had elevated NT-proBNP 
levels (p<0.0001). 
3. The diffusing capacity (DL, CO) and especially its alveolocapillary membrane 
component (DM) are decreased in acute PE. The extent of PE and the severity of RVD 
were inversely associated with DL, CO and DM; the larger the PE, the lower the DL, CO 
or DM. Although DL, CO and DM increased at the 7-month follow-up, they still remained 
lower than in healthy control subjects, especially in patients with persistent RVD. The 
reduction in DM seemed to be independent of lung volume in persistent RVD. 
4. Comparison of reflux pattern after catheter-directed and systemic thrombolysis revealed 
that local thrombolysis of ileofemoral deep venous thrombosis is associated with less 
venous reflux 2-3 years later. By reducing the incidence of venous reflux, the likelihood of 
developing PTS diminishes. 
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Value of rapid immunofluorometric D-dimer assay for exclusion of VTE 
in outpatients 
 
We were able to develop a rapid and sensitive D-dimer method in POC settings using a 
non-competitive assay design with two monoclonal antibodies (dry-reagent assay 
chemistry and time-resolved fluorometric detection). 
The analytical efficiency characteristics of this assay, including detection limit, limit of 
quantification, linearity, assay range, and precision, were quite similar to those of the 
immunoturbidimetric assays (Knecht MF et al. 1997, Bozic M et al. 2003) employed as 
comparison methods here. Nevertheless, the correlation of the new assay to these was only 
moderate (Roche TinaQuant, r=0.726) or poor (Biopool Auto Dimer, r=0.190). The 
samples obtained from patients with VTE typically gave a higher concentration in the 10-
min assay than in either of the comparison methods, which is a positive feature of the new 
assay. Because of the lack of standardization and correlation between the different 
methods, assessment of diagnostic accuracy must be performed separately for each D-
dimer method based on the clinical status of the tested patients. 
Preliminary values for sensitivity, specificity, NPV, and PPV were established by 
comparing the D-dimer concentrations obtained in outpatients with DVT and/or PE. This 
was a group of unselected outpatients with various other diseases, therefore representing 
well the population in which the assay is to be used. Because the aim here was solely to 
verify the clinical functionality of the novel assay, a more thorough clinical evaluation 
study is required to better assess the assay’s clinical performance characteristics. 
However, considering the wide range of diseases and the large number of increased D-
dimer concentrations encountered in the comparison population, the preliminary 
calculations are not likely to be unduly optimistic. D-dimer is less useful in some groups 
of patients, including those with high clinical probability of VTE, patients older than 65 
years, pregnant women, and patients admitted to hospital for another reason and in whom 
the suspicion of PE is raised during hospital stay (Righini M et al. 2005, Righini M et al. 
2008). 
Two different cut-off values, 0.6 and 1.0 mg/l, compared well with the detection limits 
typically employed in sensitive automated assays and rapid manual assays. The sensitive 
assays are sometimes criticized as being too unspecific, generating a large number of 
positive results that require further studies. Nevertheless, the cut-off level of the more 
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sensitive methods can be freely selected, and when used in combination with clinical 
probability assessment, VTE can be excluded in a significantly larger number of patients. 
In recent years, the highly sensitive D-dimer assays have been used to exclude PE in 
patients whose clinical probability for the condition is not high (Djurabi RK et al. 2009, 
Legnani C et al. 2010, Pasha SM et al. 2010, Gosselin RC et al. 2012). In our study, the 
rapid immunofluorometric assay showed value in rapid exclusion of VTE in outpatients. 
When using a quantitative ELISA or some automated turbidimetric assays, D-dimer is 
highly sensitive (more than 95%) in excluding acute DVT or PE, frequently below a 
threshold of 500 ng/l. In other studies, concentrations even lower than this have ruled out 
VTE in patients with low or intermediate clinical probability (Righini M et al. 2008, 
Goldhaber SZ et al. 2012). Within the past few years, discussion has also centered around 
how POC testing can be used to improve the efficiency of emergency department 
operations. The POC D-dimer test has been reported to be associated with a shorter 
emergency department length of stay and fewer hospital admissions (E.Lee-Lewandrowski 
et al. 2009). 
 
 
Role of helical computerized tomography (CT) in detection of RVD in 
APE patients and N-terminal pro-BNP in screening and follow-up in 
routine patient care 
 
RVD assessed on TTE has been reported to be one of the strongest predictors of early 
mortality in non-massive PE (Goldhaber SZ 2002, Kreit JW 2004). TTE examination is 
not available around the clock at all institutions, which is a limitation to its use. In recent 
years, CTPA has become the diagnostic gold standard for PE. In this prospective study 
(III), CT proved to be a practical and valuable method for detection of RVD in clinical 
practice. The incidence of RVD in this study is in line with earlier reports of APE patients 
in whom RVD was detected in CT in 58-64% (Schoepf UJ et al. 2004, Van der Meer RW 
et al. 2005, He H et al. 2006). In this study, NT-proBNP was a strong indicator of RVD. A 
normal pro-BNP level on admission excluded the development of persistent pulmonary 
hypertension during follow-up. NT-proBNP values did not have an influence on survival, 
which probably can be explained by the non-high-risk patient population. The role of NT-
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pro-BNP in predicting mortality risk could not be evaluated here. However, NT-proBNP 
on admission predicted future morbidity. Survival in this subject pool was good, even in 
the RVD-positive group. The restricted number of study patients does not, however, allow 
further conclusions about survival to be drawn. 
Numerous papers exist concerning mortality from PE, whereas the late consequences 
of PE have received little attention. It remains unclear which patients should be followed 
after acute hospital stay and standard treatment. This study revealed that normal findings 
in CT as well as an NT-proBNP level ≤350 ng/l excluded RVD both in the acute phase 
and at the 7-month follow-up. This thesis may be an aid for clinicians when considering 
which patients might benefit from follow-up. 
The cut-off level of ≤350 ng/l was chosen, although in our laboratory the references 
vary according to age and sex group, because values exceed 350 ng/l in all groups. 
Therefore, 350 ng/l is not a suitable cut-off point between “true” normal and abnormal 
values, instead indicating a slightly elevated value still low enough to detect patients who 
will benefit from a more intensive follow-up. Earlier studies of APE have used 500 ng/l 
(Pruszczyk P 2005) and 1000 ng/l (Binder L et al. 2005) as a cut-off for RVD. 
It is notable that some clinical methods have retained a strong position in clinical 
practice despite the newer diagnostic technologies. Clinical probability assessment, 
including several symptoms, signs, and risk factors, has a central role in PE diagnostics. 
ECG and arterial blood gas analysis are still today valuable clinical tools in assessing the 
probability of RVD in APE. 
CT and TTE were not performed simultaneously, which can be seen as a limitation of 
our study. However, the real-life situation is often the same. We wanted to investigate the 
role of immediate assessment of RVD by CT. The short-term prognostic significance of 
echocardiography in detecting RVD is under debate, even though several studies suggest 
that these patients are at higher risk for adverse events (Grifoni S et al. 2000, Ten Wolde 
M et al. 2004, Fremont B et al. 2008). The main purpose of detecting RVD in non-high-
risk PE might be prognostic stratification to the low- or intermediate-risk groups (Torbicki 
A et al. 2008). A recent study suggests that patients with a severe thromboembolic episode 
might constitute a high-risk group for the development of CTPH, and these patients should 
be subjected to strict follow-up with echocardiography (Otero R et al. 2011). ESC 
guidelines recommend that all APE patients showing signs of RVD at any time during 
their hospital stay should receive a follow-up echocardiography usually 3-6 months after 
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discharge (Galiè N et al. 2011). AHA guidelines recommend that patients should be 
evaluated with echocardiography as early as 6 weeks after an acute PE to screen for 
persistent pulmonary hypertension (Jaff M et al. 2011). 
Recently, CT has been used as a single procedure for diagnosis and risk stratification. 
Patients without right ventricular dysfunction at CT have a low risk of in-hospital adverse 
outcome (Becattini C et al. 2011). CT has also been useful in identifying high-risk patients 
associated with elevated biomarkers in APE where RVD/LVD showed a correlation with 
the level of NT-proBNP (Seon HJ et al. 2011). In this study, CT seems to be a reliable 
imaging method to screen RVD also in non-high-risk APE patients. All patients found to 
have chronic thromboembolic pulmonary hypertension at the 7-month follow-up had RVD 
in acute-phase CT. This indicates that when APE is diagnosed by CT, CT could be used 
also as a screening method to select patients who need to have a new RVD assessment 
later. After the 7-month follow-up, RVD was normal in the majority of patients (57/63 
patients, 90%). Normal NT-proBNP had a good negative predictive value of RVD at the 
acute phase and at 7 months. Our study results show that CT tends to be a practical 
imaging method to detect RVD in APE. Furthermore, elevated NT-proBNP appears to be 
a good and valuable tool in assessing RVD in patients with APE both in the acute phase 
and during follow-up. 
Based on our results, we suggest the following follow-up protocol. Patients with RVD 
on admission CT should be rescreened with natriuretic peptide assessment at follow-up 
and if elevated an echocardiography should be performed. Timing for screening seems 
reasonable at the visit when warfarin is to be discontinued. Alternatively, if 
anticoagulation therapy is to be continuous at discharge, then biomarker screening might 
be done during a routine follow-up visit 6-12 months after APE. The suggested protocol 
needs to be validated in a larger patient population. 
 
 
Reduction of membrane component of diffusing capacity is associated 
with the extent of acute pulmonary embolism 
 
DL, CO and especially DM are decreased in acute PE. At the 7-month follow-up, they 
remained lower than in healthy control subjects, especially in patients with persistent 
RVD. To the best of our knowledge, this was also the first study to use the CT-based 
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scoring of mass of embolism in relation to the components of diffusing capacity. This 
study yielded new information about the effects of PE on lung function. 
A previous study (Fennerty et al.1988) used a ventilation-perfusion isotope scan with 
only a crude estimation of the size of PE. In the present study, a more exact 
characterization of the embolism mass was obtained. The results indicate that also the area 
of the alveolocapillary membrane affected by the thrombus, i.e. the extent of PE, is 
responsible for a reduction in DL, CO at the acute phase of PE, in addition to the effect of 
a reduction in lung volume. Loss of lung volume is important in the mechanism of 
decreased DL, CO explained by atelectasis, bronchoconstriction, and local pulmonary 
edema occurring in terminal respiratory units corresponding to the site of PE (Nadel JA et 
al. 1964). 
DM/Vc was lower in patients with RVD than in those without RVD, suggesting a role 
for DM/Vc in the pathophysiology of RVD. Earlier studies (Oppenheimer BW 2006) have 
proposed that a reduction in the capillary volume in PE causes vascular dilatation and 
leads to a lower DM/Vc ratio. In this study, there were improvements in both DM and Vc, 
and thus, their relation might not change significantly at follow-up. 
 
 
Catheter-directed thrombolysis of ileofemoral deep venous thrombosis 
reduces venous reflux 
 
In 2003, when Study IV was performed, catheter-directed thrombolysis was a fairly new 
treatment method for DVT. We were living in a transition period, moving from systemic 
thrombolysis towards catheter-directed thrombolysis. Both methods were in use in clinical 
practice, which offered us an excellent opportunity to compare their late effects. The long-
term goal of treatment of an acute DVT episode is mainly the prevention of PTS. Rapid 
thrombus resolution may offer potential for prevention of PTS based on its known 
favorable effect on the preservation of venous valvular function (Janssen et al. 2005). The 
study results showed that patients treated with catheter-directed thrombolysis in the acute 
phase had significantly less reflux at follow-up 2-3 years later. 
In this retrospective, non-randomized study, the baseline status of patients was 
comparable. However, potential differences between the two groups cannot be excluded. 
Valvular competence was confirmed better in patients with catheter-directed thrombolysis 
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than in systemic thrombolysis-treated patients. Retrospective patient sampling did not 
allow a detailed analysis of imaging data before the treatment. A venography was 
performed on patients in the catheter-directed lysis group both before and after lysis. In 
the systemic lysis group, the imaging method was compression ultrasound, and a control 
imaging was only performed if the result of the lysis seemed clinically inadequate. 
Patients in the catheter-directed lysis-treated group were evaluated more precisely. The 
control venography also offered an immediate possibility for the interventional radiologist 
to detect an underlying lesion and use intravenous procedures, such as venous angioplasty 
and stenting, when needed. 
Significantly less deep reflux and superficial reflux were observed in catheter-treated 
patients than in systemic-treated patients. These results are in line with other studies. The 
data of the systematic review of systemic and local-regional thrombolytic therapy suggest 
catheter-directed thrombolytic therapy decreases the incidence of post-thrombotic 
syndrome (Alesh I et al. 2007). In another systematic review and meta-analysis, besides a 
decrease in the incidence of post-thrombotic syndrome and venous obstruction, the results 
suggested that surgical thrombectomy seems to decrease the incidence of PTS and venous 
reflux (Casey ET et al. 2012). Clinical outcome at 2-3 years after catheter-directed or 
systemically administered thrombolytic therapy for iliofemoral DVT did not differ 
between the two treatment groups. However, a trend emerged towards less symptoms in 
the catheter-directed treatment group. 
In recent years, the growing interest in endovascular technologies has led to the 
development of a variety of minimally invasive, catheter-based strategies to deal with 
venous thrombi. These technologies combine catheter-directed thrombolytic infusion, 
venous angioplasty, percutaneous mechanical thrombectomy, mechanical fragmentation, 
or ultrasound energy to remove the intraluminal thrombus (Lin PH et al. 2008, Nazir SA et 
al. 2009, Lin PH et al. 2010). Patients in whom thrombolytic treatment is being considered 
should undergo careful evaluation for contraindications of thrombolytic treatment and 
risks for bleeding as well as clinical evaluation of the severity of DVT. Selecting the 
patients, especially those at low risk of bleeding and with a high proximal DVT, who can 
benefit the most from aggressive thrombolytic treatment improves outcome, making the 
intervention more cost-effective (Enden T et al. 2013). Endovascular thrombolytic therapy 
procedures often require centralization to centers where an experienced interventional 
radiologist is available. 
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7. SUMMARY AND CONCLUSIONS 
 
 
 
The main conclusions of the present studies can be summarized as 
follows: 
 
1. The rapid and sensitive 10-min D-dimer assay seems to be suitable for excluding VTE 
in POC settings. Due to the high preliminary sensitivity and NPV obtained here, the assay 
could potentially be employed as a stand-alone test given that a sufficiently low cut-off 
level was selected. Alternatively, combined with clinical probability assessment, a higher 
cut-off level could be employed to increase the specificity of the assay. 
2. CT is a practical and valuable imaging method for detection of RVD in non-high-risk 
APE patients. All patients found to have RVD at the 7-month follow-up had RVD also in 
the acute-phase CT and TTE. Furthermore, normal RV findings in CT as well as normal 
NT-proBNP level excluded RVD both in the acute phase and at the 7-month follow-up. 
According to study results, a follow-up protocol is suggested. Patients with RVD on 
admission CT should be rescreened with natriuretic peptide assessment at follow-up and if 
elevated an echocardiography is recommended.  
3. The extent of PE and the consecutive signs of RVD were associated with a decrease in 
diffusion of membrane at both the acute phase and the resolution phase of PE independent 
of lung volume changes. In patients with permanent RVD, also the total diffusing capacity 
remained decreased in the follow-up. While the diffusing capacity recovered somewhat 
during the 7-month follow-up, it did not reach the level of healthy controls or the normal 
reference range. The data provide new knowledge of the consequences of PE on lung 
function and indicate that sustained reduction of diffusing capacity may remain despite 
treatment of PE according to current guidelines. 
4. Catheter-directed thrombolysis for DVT at the acute event reduced both deep and 
superficial reflux at the 2- to 3-year follow-up. By reducing the incidence of venous 
reflux, the likelihood of developing PTS diminishes as well. 
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